Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; and intends to launch PoloMeds for diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker’s nevus, vitiligo, and other common skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
Polomar Health Services Strengthens Board Leadership to Support Standalone Growth Strategy
Polomar Health Services appointed George Hornig as Executive Chairman and added three new directors, including George Caruolo as Lead Independent Director, to support its standalone growth strategy.
The new board members bring extensive experience in public markets, healthcare, and technology from roles at Tesla, Xometry, and Deutsche Bank.
Management is currently reviewing its commercial priorities and product mix, with a broader business update expected to follow the completion of this review.